Summary
The pharmacokinetics of the H2-receptor antagonist famotidine, after oral administration of a 20 mg tablet, has been studied in 10 elderly patients with normal renal function (CLCR≧59 ml·min−1, Mean=80 ml·min−1), 5 elderly patients with renal insufficiency (CLCR≦38 ml·min−1, Mean=15 ml·min−1), and 6 healthy young volunteers.
Elimination half-life in the elderly patients with renal insufficiency was significantly prolonged compared to the elderly patients with normal renal function and the young volunteers. The correlation coefficient between creatinine clearance and the elimination rate constant of famotidine was 0.672. Mean urinary recovery of unchanged drug up to 24 h in the young volunteers was 44%. The mean renal clearance of famotidine in the young volunteers (270 ml·min−1) was substantially greater than the creatinine clearance, 128 ml·min−1, which suggests the possibility of tubular secretion of famotidine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ventkateswaran PS, Jeffers A, Hocken AG (1972) Gastric secretion in chronic renal failure. Br Med J 4: 22–23
Pendleton RG, Torchiana ML, Chung C, Cook P, Wiese S, Clineschmidt BV (1983) Studies on MK-208 (YM-11170) a new, slowly dissociable H2-receptor antagonist. Arch Int Pharmacodyn Ther 266: 4–16
Smith JL, Gamal M, Chremos AN, Graham DY (1985) Famotidine, a new H2-receptor antagonist: Effect on parietal, non-parietal and pepsin secretion in man. Dig Dis Sci 4: 308–312
Dammann HG, Muller P, Simon B (1983) 24 Hour intragastric acidity and single night-time dose of three H2-blockers. Lancet 2: 1078
Humphries TJ (1987) Famotidine: A notable lack of drug interactions. Scand J Gastroenterol 22: 55–60
John WR, Reubin A, Jordan DT, Arthur HN, Nathan WS (1976) The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study. J Gerontol 31: 155–163
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41
Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR (1987) Disposition of famotidine in renal insufficiency, J Clin Pharmacol 27: 782–787
Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, Hattori N (1985) Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. Eur J Clin Pharmacol 28: 327–331
Miwa M, Tani N, Miwa T (1984) Inhibition of gastric secretion by a new H2-antagonist, YM-11170 in healthy subjects. Int J Clin Pharmacol Ther Toxicol 22: 214–217
Redolfi A, Borgogelli E, Lodola E (1979) Blood level of cimetidine in relation to age. Eur J Clin Pharmacol 15: 257–261
Garg DC, Baltodano N, Jallad NS, Perez G, Oster JR, Eshelman FN, Weidler DJ (1986) Pharmacokinetics of ranitidine in patients with renal failure. J Clin Pharmacol 26: 286–291
Chau NP, Zech PY, Pozet N, Hadi-Aissa A (1982) Ranitidine kinetics in normal subjects. Clin Pharmacol Ther 31: 770–774
Garg DC, Weidler DJ, Eshelman FN (1983) Ranitidine bioavailability and kinetics in normal male subjects. Clin Pharmacol Ther 33: 445–452
Lin JH, Chremos AN, Yeh KC, Antonello J, Hessey GA (1988) Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. Eur J Clin Pharmacol 34: 41–46
Kawai R, Yamada S, Kawamura S, Miwa T, Miwa M (1984) Metabolic fate of famotidine (YM-11170), a new potent H2-receptor antagonist (2). Absorption and excretion in dogs and humans. Pharmacometrics 27: 73–77
Smith JL (1985) Clinical pharmacology of famotidine. Digestion 32: 15–23
Ohashi K, Aso R, Suzuki K (1987) Is the bioavailability of famotidine reduced by an antacid? Jpn J Clin Pharmacol Ther 18: 589–593
Kroemer H, Klotz U (1987) Pharmacokinetics of famotidine in man. Int J Clin Pharmacol Ther Toxicol 25: 458–463
Schentag JJ, Cerra FB, Calleri GM, Leising ME, French MA, Bernhard H (1981) Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 29: 737–743
Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, Antonello J, Vlasses P, Ryan JR, Williams RL (1987) Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. Biopharm Drug Dispos 8: 549–560
Abraham PA, Opsahl JA, Halstenson CE, Chremos AN, Matzke GR, Keane WF (1987) The effects of famotidine on renal function in patients with renal insufficiency. Br J Clin Pharmacol 24: 385–389
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Inotsume, N., Nishimura, M., Fujiyama, S. et al. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers. Eur J Clin Pharmacol 36, 517–520 (1989). https://doi.org/10.1007/BF00558079
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558079